Jasper Therapeutics, (id:5802 JSPR)
22.05 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 1:14:00 PM)
Exchange closed, opens in 1 day 20 hours
About Jasper Therapeutics,
Market Capitalization 330.78M
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
| Headquarters (address) |
2200 Bridge Pkwy Redwood City 94065 CA United States |
| Phone | 650 549 1400 |
| Website | https://www.jaspertherapeutics.com/ |
| Employees | 45 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | JSPR |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 4.00 - 31.01 |
| Market Capitalization | 330.78M |
| P/E trailing | -3.57 |
| P/E forward | -4.88 |
| Price/Book | 3.95 |
| Beta | 2.20 |
| EPS | -4.75 |
| EPS United States (ID:6, base:3399) | 24.27 |